CHMP recommends RYBREVANT ® ▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib
1,2,3,4
In the MARIPOSA-2 study, amivantamab in...
Zur Pressemeldung auf www.jnj.com